MarketAxess vs AbbVie

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbbVie leads in AI visibility (90 vs 72)

MarketAxess

LeaderConsumer Finance

Enterprise

New York electronic bond trading (NASDAQ: MKTX) $763M FY2024 revenue; Open Trading $2T+ liquidity, 40% US IG bond electronification, portfolio trading growth competing with Tradeweb and Bloomberg.

AI VisibilityBeta
Overall Score
B72
Category Rank
#64 of 290
AI Consensus
69%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
77
Gemini
67

About

MarketAxess Holdings Inc. is a New York City-based electronic fixed income trading platform — publicly traded on the NASDAQ (NASDAQ: MKTX) as an S&P 500 Financials component — operating the leading electronic trading marketplace for US investment-grade corporate bonds, US high-yield bonds, emerging market bonds, municipal bonds, and US Treasury securities through approximately 850 employees globally. In fiscal year 2024, MarketAxess reported revenues of $763 million with record trading volumes in US investment-grade bonds and emerging market credit, as the multi-year electronification trend in bond markets continued to shift institutional fixed income trading from voice broker-dealer phone execution to electronic all-to-all trading on MarketAxess's Open Trading marketplace. CEO Chris Concannon (joined 2023, formerly Cboe Global Markets president) leads MarketAxess's strategy of expanding market share beyond the institutional investment-grade core into rate products (US Treasuries, agency securities), high-yield, and portfolio trading as fixed income electronification accelerates — currently approximately 40% of US investment-grade bonds trade electronically versus 15% in 2015. MarketAxess's Open Trading protocol (anonymous all-to-all price discovery between buy-side, sell-side, and market makers) generated over $2 trillion in liquidity provision in 2024, reducing transaction costs versus bilateral dealer quotes by an average of $0.28 per $100 face value.

Full profile

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A90
Category Rank
#9 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
99
Gemini
83

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

AI Visibility Head-to-Head

72
Overall Score
90
#64
Category Rank
#9
69
AI Consensus
60
stable
Trend
stable
78
ChatGPT
99
77
Perplexity
99
67
Gemini
83
79
Claude
96
79
Grok
95

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.